This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently Amended) ~~Compounds~~ A compound of ~~the~~ formula I



I

in which

D denotes aromatic carbo- or heterocycle having 0 to 4 N, O and/or S atoms which is unsubstituted or mono- or polysubstituted by Hal, A, OR^2, $N(R^2)_2$, NO_2, CN, $COOR^2$ or $CON(R^2)_2$,

X denotes -C=O or $C(R^3)_2$,

W denotes $-[C(R^3)_2]_n-$,

R^1 denotes H or A, which may be substituted by OR^3, $S(O)_nR^3$, $N(R^3)_2$, CN, $COOR^3$, $CON(R^3)_2$, $OCON(R^3)_2$, $N(R^3)COOR^3$, $N(R^3)CON(R^3)_2$, $N(R^3)SO_2R^3$, $SO_2N(R^3)_2$ or -C≡C-,

R^2 denotes H, A, $-[C(R^3)_2]_n$-Ar', $-[C(R^3)_2]_n$-Het', $-[C(R^3)_2]_n$-cycloalkyl, $-[C(R^3)_2]_n-N(R^3)_2$ or $-[C(R^3)_2]_n-OR^3$,

R^3 denotes H or A,

Y denotes alkylene, cycloalkylene, Het-diyl or Ar-diyl,

T denotes a mono- or bicyclic saturated, unsaturated or aromatic carbo- or heterocycle having 0 to 4 N, O and/or S atoms which is mono- or disubstituted by =O, =S, $=NR^2$, =N-CN, $=N-NO_2$, $=NOR^2$, $=NCOR^2$, $=NCOOR^2$, and/or $=NOCOR^2$ and may furthermore be mono-, di- or trisubstituted by R^2, Hal, A, $-[C(R^3)_2]_n$-Ar, $-[C(R^3)_2]_n$-Het, $-[C(R^3)_2]_n$-cycloalkyl, OR^2, $N(R^2)_2$, NO_2, CN, $COOR^2$, $CON(R^2)_2$, NR^2COA, $NR^2CON(R^2)_2$, NR^2SO_2A, COR^2, SO_2NR^2 and/or $S(O)_nA$,

A denotes unbranched or branched alkyl having 1-10 C atoms, in which one or two CH_2 groups may be replaced by O or S atoms and/or by -CH=CH- groups and/or ~~also~~ 1-7 H atoms may be replaced by F,

Ar denotes phenyl, naphthyl or biphenyl, each of which is unsubstituted or mono-, di- or trisubstituted by Hal, A, OR^2, $N(R^2)_2$, NO_2, CN, $COOR^2$, $CON(R^2)_2$, NR^2COA,

$NR^2CON(R^2)_2$, NR^2SO_2A, COR^2, $SO_2N(R^2)_2$, $S(O)_nA$, $-[C(R^3)_2]_n-COOR^2$ or $-O-[C(R^3)_2]_o-COOR^2$,

Ar' denotes phenyl which is unsubstituted or mono-, di- or trisubstituted by Hal, A, OR^3, $N(R^3)_2$, NO_2, CN, $COOR^3$, $CON(R^3)_2$, NR^3COA, $NR^3CON(R^3)_2$, NR^3SO_2A, COR^3, $SO_2N(R^3)_2$, $S(O)_nA$, $-[C(R^3)_2]_n-COOR^3$ or $-O-[C(R^3)_2]_o-COOR^3$,

Het denotes a mono- or bicyclic saturated, unsaturated or aromatic heterocycle having 1 to 4 N, O and/or S atoms, which may be unsubstituted or mono-, di- or trisubstituted by carbonyl oxygen, =S, $=N(R^2)_2$, Hal, A, $-[C(R^3)_2]_n-Ar$, $-[C(R^3)_2]_n-Het'$, $-[C(R^3)_2]_n-$cycloalkyl, $-[C(R^3)_2]_n-OR^2$, $-[C(R^3)_2]_n-N(R^3)_2$, NO_2, CN, $-[C(R^3)_2]_n-COOR^{2'}$, $-[C(R^3)_2]_n-CON(R^2)_2$, $-[C(R^3)_2]_n-NR^2COA$, $NR^2CON(R^2)_2$, $-[C(R^3)_2]_n-NR^2SO_2A$, COR^2, SO_2NR^2 and/or $S(O)_nA$,

Het' denotes a mono- or bicyclic saturated, unsaturated or aromatic heterocycle having 1 to 4 N, O and/or S atoms, which may be unsubstituted or mono- or disubstituted by carbonyl oxygen, =S, $=N(R^3)_2$, Hal, A, OR^3, $N(R^3)_2$, NO_2, CN, $COOR^3$, $CON(R^3)_2$, NR^3COA, $NR^3CON(R^3)_2$, NR^3SO_2A, COR^3, SO_2NR^3 and/or $S(O)_nA$,

Hal denotes F, Cl, Br or I,

m denotes 1 or 2,

n denotes 0, 1 or 2, and

o denotes 1, 2 or 3,

~~and~~ or a pharmaceutically ~~usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios~~ acceptable salt, hydrate, alcoholate or stereoisomer thereof, or a mixture thereof.

2. (Currently Amended) ~~Compounds~~ A compound according to Claim 1, in which

D denotes an aromatic five-ring heterocycle having 1 to 2 N, O and/or S atoms which is unsubstituted or mono- or disubstituted by Hal,

~~and~~ or a pharmaceutically ~~usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios~~ acceptable salt, hydrate, alcoholate or stereoisomer thereof, or a mixture thereof.

3. (Currently Amended) ~~Compounds~~ A compound according to Claim 1, in which

D denotes a thienyl ring which is mono- or disubstituted by Hal,

~~and~~ or a pharmaceutically ~~usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios~~ acceptable salt, hydrate, alcoholate or stereoisomer thereof, or a mixture thereof.

4. (Currently Amended) ~~Compounds~~ A compound according to claim 1, in which

R^2 denotes H or alkyl having 1, 2, 3, 4, 5 or 6 C atoms,

~~and~~ or a pharmaceutically ~~usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios~~ acceptable salt, hydrate, alcoholate or stereoisomer thereof, or a mixture thereof.

5. (Currently Amended) ~~Compounds~~ A compound according to claim 1, in which

R^1 denotes H or A, which may be substituted by OR^3, $CON(R^3)_2$, $N(R^3)_2$, $S(O)_nR^3$, $COOR^3$, $OCON(R^3)_2$, $N(R^3)COOR^3$ or -C≡C-,

~~and~~ or a pharmaceutically ~~usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios~~ acceptable salt, hydrate, alcoholate or stereoisomer thereof, or a mixture thereof.

6. (Currently Amended) ~~Compounds~~ A compound according to claim 1, in which

X denotes -C=O,

~~and~~ or a pharmaceutically ~~usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios~~ acceptable salt, hydrate, alcoholate or stereoisomer thereof, or a mixture thereof.

7. (Currently Amended) ~~Compounds~~ A compound according to claim 1, in which

W is absent,

~~and~~ or a pharmaceutically ~~usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios~~ acceptable salt, hydrate, alcoholate or stereoisomer thereof, or a mixture thereof.

8. (Currently Amended) ~~Compounds~~ A compound according to claim 1, in which

Y denotes Ar-diyl,

~~and~~ or a pharmaceutically ~~usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios~~ acceptable salt, hydrate, alcoholate or stereoisomer thereof, or a mixture thereof.

9. (Currently Amended) ~~Compounds~~ A compound according to claim 1, in which

T denotes a mono- or bicyclic saturated, unsaturated or aromatic heterocycle having 1 to 2 N and/or O atoms which is mono- or disubstituted by =O, =S, $=NR^2$, =N-CN, $=N-NO_2$, $=NOR^2$, $=NCOR^2$, $=NCOOR^2$ or $=NOCOR^2$ and may furthermore be mono- or disubstituted by Hal or A,

~~and~~ or a pharmaceutically ~~usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios~~ acceptable salt, hydrate, alcoholate or stereoisomer thereof, or a mixture thereof.

10. (Currently Amended) ~~Compounds~~ A compound according to claim 1, in which

T denotes a mono- or bicyclic saturated or unsaturated heterocycle having 1 to 2 N and/or O atoms which is mono- or disubstituted by =O, =S or =NH,

~~and~~ or a pharmaceutically ~~usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios~~ acceptable salt, hydrate, alcoholate or stereoisomer thereof, or a mixture thereof.

11. (Currently Amended) ~~Compounds~~ A compound according to claim 1, in which

T denotes piperidin-1-yl, pyrrolidin-1-yl, pyridin-1-yl, morpholin-4-yl, piperazin-1-yl, 1,3-oxazolidin-3-yl, pyridazin-2-yl, pyrazin-1-yl, azepan-1-yl or 2-azabicyclo[2.2.2]-octan-2-yl, each of which is mono- or disubstituted by =O or =NH,

~~and~~ or a pharmaceutically ~~usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios~~ acceptable salt, hydrate, alcoholate or stereoisomer thereof, or a mixture thereof.

12. (Currently Amended) ~~Compounds~~ A compound according to claim 1, in which

Ar denotes phenyl which is unsubstituted or mono- or disubstituted by Hal, A, OA, SO_2A, $COOR^2$, SO_2NH_2 or CN,

~~and~~ or a pharmaceutically ~~usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios~~ acceptable salt, hydrate, alcoholate or stereoisomer thereof, or a mixture thereof.

13. (Currently Amended) ~~Compounds~~ A compound according to claim 1, in which

Ar denotes phenyl which is unsubstituted or mono- or disubstituted by A and/or Hal,

~~and~~ or a pharmaceutically ~~usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios~~ acceptable salt, hydrate, alcoholate or stereoisomer thereof, or a mixture thereof.

14. (Currently Amended) ~~Compounds~~ A compound according to claim 1, in which

D denotes aromatic five-ring heterocycle having 1 to 2 N, O and/or S atoms which is unsubstituted or mono- or disubstituted by Hal,

R^1 denotes H or A, which may be substituted by OR^3, $CON(R^3)_2$, $N(R^3)_2$, $S(O)_nR^3$, $COOR^3$, $OCON(R^3)_2$, $N(R^3)COOR^3$ or -C≡C-,

R^2 denotes H or alkyl having 1, 2, 3, 4, 5 or 6 C atoms,

X denotes -C=O or CH_2,

W is absent,

Y denotes Ar-diyl,

Ar denotes phenyl which is unsubstituted or mono- or disubstituted by A and/or Hal, and

T denotes a mono- or bicyclic saturated or unsaturated heterocycle having 1 to 2 N and/or O atoms which is mono- or disubstituted by =O, =S or =NH,

~~and~~ or a pharmaceutically ~~usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios~~ acceptable salt, hydrate, alcoholate or stereoisomer thereof, or a mixture thereof.

15. (Currently Amended) ~~Compounds~~ A compound according to claim 1, in which

D denotes thienyl, thiazolyl or furyl, each of which is mono- or disubstituted by Hal,

R^1 denotes H or A, which may be substituted by OR^3, $CON(R^3)_2$, $N(R^3)_2$, $S(O)_nR^3$, $COOR^3$, $OCON(R^3)_2$, $N(R^3)COOR^3$ or -C≡C-,

R^2 denotes H or alkyl having 1, 2, 3, 4, 5 or 6 C atoms,

X denotes -C=O or CH_2,

W is absent,

Y denotes Ar-diyl,

Ar denotes phenyl which is unsubstituted or mono- or disubstituted by A and/or Hal, and

T denotes piperidin-1-yl, pyrrolidin-1-yl, pyridin-1-yl, morpholin-4-yl, piperazin-1-yl, 1,3-oxazolidin-3-yl, pyridazin-2-yl, pyrazin-1-yl, azepan-1-yl or 2-azabicyclo-[2.2.2]octan-2-yl, each of which is mono- or disubstituted by =O or =NH,

~~and~~ or a pharmaceutically ~~usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios~~ acceptable salt, hydrate, alcoholate or stereoisomer thereof, or a mixture thereof.

16. (Currently Amended) ~~Compounds~~ A compound according to claim 1, in which

D denotes thienyl or phenyl, each of which is mono- or disubstituted by Hal,

R^1 denotes H or A, which may be substituted by OR^3, $CON(R^3)_2$, $N(R^3)_2$, $S(O)_nR^3$, $COOR^3$, $OCON(R^3)_2$, $N(R^3)COOR^3$ or -C≡C-,

R^2 denotes H or alkyl having 1, 2, 3, 4, 5 or 6 C atoms,

R^3 denotes H or alkyl having 1, 2, 3, 4, 5 or 6 C atoms,

X denotes -C=O or CH_2,

W is absent or denotes CH_2,

Y denotes Ar-diyl,

A denotes alkyl having 1, 2, 3, 4, 5 or 6 C atoms, in which one or two CH_2 groups may be replaced by O or S atoms and/or by –CH=CH- groups and/or also 1-7 H atoms may be replaced by F,

Ar denotes phenyl which is unsubstituted or mono- or disubstituted by A and/or Hal, and

T denotes piperidin-1-yl, pyrrolidin-1-yl, pyridin-1-yl, morpholin-4-yl, piperazin-1-yl, 1,3-oxazolidin-3-yl, pyridazin-2-yl, pyrazin-1-yl, azepan-1-yl or 2-azabicyclo-[2.2.2]octan-2-yl, each of which is mono- or disubstituted by =O or =NH,

~~and~~ or a pharmaceutically ~~usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios~~ acceptable salt, hydrate, alcoholate or stereoisomer thereof, or a mixture thereof.

17. (Currently Amended) ~~Compounds~~ A compound according to Claim 1, ~~selected from the group~~ which is

(S)-2-([(5-chlorothiophene-2-carbonyl)amino]-*N*-[4-(3-oxomorpholin-4-yl)phenyl]-4-methylvaleramide,

(S)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]-4-methylvaleramide,

(S)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[4-(2-oxo-2*H*-pyrazin-1-yl)phenyl]-4-methylvaleramide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[4-(3-oxomorpholin-4-yl)phenyl]-4-methylvaleramide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]-4-methylvaleramide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[4-(2-oxo-2*H*-pyrazin-1-yl)phenyl]-4-methylvaleramide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[4-(2-oxo-2*H*-pyridin-1-yl)phenyl]-4-methylvaleramide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[4-(2-iminopiperidin-1-yl)phenyl]-4-methylvaleramide,

(S)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[4-(2-iminopiperidin-1-yl)phenyl]-4-

methylvaleramide,

2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[3-methyl-4-(2-oxopiperidin-1-yl)phenyl]acetamide,

3-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[3-methyl-4-(2-oxopiperidin-1-yl)phenyl]propionamide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]propionamide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]-3-methylbutyramide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]butyramide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]valeramide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]-3-aminocarbonylpropionamide,

(R)-2-[(4-chlorophenylcarbonyl)amino]-*N*-[4-(3-oxomorpholin-4-yl)phenyl]-4-methylvaleramide,

(R)-2-[(4-chlorophenylcarbonyl)amino]-*N*-[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]-4-methylvaleramide,

2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]-3-(*N*,*N*-dimethylamino)propionamide,

(R)-2-[(5-bromothiophene-2-carbonyl)amino]-*N*-[4-(3-oxomorpholin-4-yl)phenyl]-4-methylvaleramide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[4-(2-oxopiperidin-1-yl)benzyl]-4-methylvaleramide,

2-[(5-chlorothiophene-2-methyl)amino]-*N*-[4-(3-oxomorpholin-4-yl)phenyl]-4-methylvaleramide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[4-(3-oxomorpholin-4-yl)phenyl]-3-methylsulfanylpropionamide,

(S)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[4-(2-oxopiperidin-1-yl)benzyl]-4-methylvaleramide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[4-(3-oxomorpholin-4-yl)phenyl]-3-methylbutyramide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[4-(2-oxo-2*H*-pyridin-1-yl)phenyl]-3-methylbutyramide,

3-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[4-(3-oxomorpholin-4-yl)-phenyl]propionamide,

3-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]propionamide,

3-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[4-(2-oxo-2*H*-pyridin-1-yl)phenyl]propionamide,

2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]acetamide,

2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[4-(3-oxomorpholin-4-yl)-phenyl]acetamide,

2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[4-(2-oxo-2*H*-pyridin-1-yl)phenyl]acetamide,

3-[(5-chlorothiophene-2-carbonyl)amino]-N-[4-(2-oxo-2*H*-pyridin-1-yl)phenyl]-2-butylpropionamide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[4-(3-oxomorpholin-4-yl)-phenyl]propionamide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[4-(3-oxomorpholin-4-yl)-phenyl]valeramide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[4-(2-oxo-2*H*-pyridin-1-yl)phenyl]-3-methylsulfanylpropionamide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[4-(2-oxo-2*H*-pyrazin-1-yl)-phenyl]propionamide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[4-(3-oxomorpholin-4-yl)phenyl]-4-methylsulfanylbutyramide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[4-(3-oxomorpholin-4-yl)-phenyl]butyramide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[4-(3-oxomorpholin-4-yl)phenyl]-3-ethynylpropionamide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[3-methyl-4-(3-oxomorpholin-4-yl)-phenyl]-3-ethynylpropionamide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[3-fluoro-4-(3-oxomorpholin-4-yl)-phenyl]propionamide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[3-methyl-4-(3-oxomorpholin-4-yl)-phenyl]-4-methylsulfanylbutyramide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[4-(3-oxomorpholin-4-yl)phenyl]-3-(*tert*-butyloxycarbonyl)propionamide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[4-(3-oxomorpholin-4-yl)phenyl]-3-vinylpropionamide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[3-methyl-4-(3-oxomorpholin-4-yl)-phenyl]-3-vinylpropionamide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[3-methyl-4-(3-oxomorpholin-4-yl)-phenyl]-3-(*tert*-butyloxycarbonyl)propionamide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[4-(3-oxomorpholin-4-yl)phenyl]-4-methoxybutyramide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]-4-methoxybutyramide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[3-fluoro-4-(3-oxomorpholin-4-yl)phenyl]-4-methylvaleramide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[3-fluoro-4-(3-oxomorpholin-4-yl)phenyl]valeramide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[3-chloro-4-(3-oxomorpholin-4-yl)phenyl]propionamide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[4-(3-oxomorpholin-4-yl)phenyl]-4-(*tert*-butyloxycarbonyl)butyramide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]-4-(*tert*-butyloxycarbonyl)butyramide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[4-(2-oxopiperidin-1-yl)phenyl]-4-(*tert*-butyloxycarbonyl)butyramide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[4-(3-oxomorpholin-4-yl)phenyl]-4-(*tert*-butyloxycarbonylamino)butyramide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[3-methyl-4-(3-oxomorpholin-4-yl)-phenyl]-4-(*tert*-butyloxycarbonylamino)butyramide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[4-(3-oxomorpholin-4-yl)phenyl]-5-(*tert*-butyloxycarbonylamino)valeramide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[3-methyl-4-(3-oxomorpholin-4-yl)-phenyl]-5-(*tert*-butyloxycarbonylamino)valeramide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[4-(3-oxomorpholin-4-yl)phenyl]-3-(*tert*-butyloxycarbonylamino)propionamide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[3-methyl-4-(3-oxomorpholin-4-yl)-phenyl]-3-(*tert*-butyloxycarbonylamino)propionamide,

(R)-3-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[3-methyl-4-(3-oxomorpholin-4-yl)-phenyl]butyramide,

(R)-3-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[3-methyl-4-(3-oxomorpholin-4-yl)-phenyl]-5-methyladipamide,

(S)-3-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[3-methyl-4-(3-oxomorpholin-4-yl)-phenyl]-5-methyladipamide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[4-(2-oxo-2*H*-pyridin-1-yl)phenyl]-3-methoxypropionamide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[3-methyl-4-(3-oxomorpholin-4-yl)-phenyl]-3-methoxypropionamide,

(2R,3R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[4-(3-oxo- morpholin-4-yl)-phenyl]-3-methoxybutyramide,

(2R,3R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]-3-methoxybutyramide,

(S)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[3-methyl-4-(3-oxomorpholin-4-yl)-phenyl]-3-methoxypropionamide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[3-trifluoromethyl-4-(3-oxomorpholin-4-yl)phenyl]-3-methoxypropionamide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[3-chloro-4-(2-azabicyclo[2.2.2]-octan-2-yl)phenyl]-3-methoxypropionamide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[3-trifluoromethoxy-4-(2-azabicyclo-[2.2.2]octan-2-yl)phenyl]-3-methoxypropionamide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[3-chloro-4-(3-oxomorpholin-4-yl)-phenyl]-3-methoxypropionamide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[3-fluoro-4-(3-oxomorpholin-4-yl)-phenyl]-3-methoxypropionamide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[3-chloro-4-(2-oxo-2*H*-pyridin-1-yl)-phenyl]-3-methoxypropionamide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[3-methyl-4-(3-oxomorpholin-4-yl)-phenyl]-3-allylpropionamide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[3-methyl-4-(3-oxomorpholin-4-yl)-phenyl]-3-propoxypropionamide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[3-methyl-4-(3-oxomorpholin-4-yl)-phenyl]-3-ethoxypropionamide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[3-methyl-4-(3-oxomorpholin-4-yl)-phenyl]-3-(2-methoxyethoxy)propionamide,

(2R,3R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]-3-ethoxybutyramide,

(2R,3R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]-3-(2-methoxyethoxy)butyramide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[3-methyl-4-(3-oxomorpholin-4-yl)-phenyl]-3-methylsulfonylpropionamide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[4-(2-oxo-2*H*-pyridin-1-yl)phenyl]-3-methylsulfonylpropionamide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[4-(3-oxomorpholin-4-yl)phenyl]-3-methylsulfonylpropionamide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[4-(3-oxomorpholin-4-yl)phenyl]-3-methylsulfonylbutyramide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]-3-methylsulfonylbutyramide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[4-(2-oxo-2*H*-pyridin-1-yl)phenyl]-3-methylsulfonylbutyramide,

(R)-2-[(5-chlorothiophen-2-ylmethyl)amino]-*N*-[4-(3-oxomorpholin-4-yl)-phenyl]valeramide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[4-(3-oxomorpholin-4-yl)phenyl]-3-carboxypropionamide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[3-methyl-4-(3-oxomorpholin-4-yl)-phenyl]-3-carboxypropionamide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[4-(3-oxomorpholin-4-yl)phenyl]-4-carboxybutyramide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[3-methyl-4-(3-oxomorpholin-4-yl)-phenyl]-4-carboxybutyramide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[4-(3-oxomorpholin-4-yl)phenyl]-4-aminobutyramide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[3-methyl-4-(3-oxomorpholin-4-yl)-phenyl]-4-aminobutyramide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[4-(3-oxomorpholin-4-yl)phenyl]-5-aminovaleramide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[3-methyl-4-(3-oxomorpholin-4-yl)-phenyl]-5-aminovaleramide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[4-(3-oxomorpholin-4-yl)phenyl]-3-aminopropionamide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[3-methyl-4-(3-oxomorpholin-4-yl)-phenyl]-3-aminopropionamide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]-3-hydroxypropionamide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[3-4-(3-oxomorpholin-4-yl)phenyl]-3-hydroxypropionamide,

(2R,3R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[4-(3-oxomorpholin-4-yl)phenyl]-3-hydroxybutyramide,

(2R,3R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[4-(3-oxomorpholin-4-yl)phenyl]-3-aminocarbonyloxybutyramide,

(2R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]-3-aminocarbonyloxypropionamide, or

(2R,3R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]-3-aminocarbonyloxybutyramide,

~~and~~ or a pharmaceutically ~~usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios~~ acceptable salt, hydrate, alcoholate or stereoisomer thereof, or a mixture thereof.

18. (Withdrawn and Currently Amended) ~~Process~~ A process for ~~the preparation of compounds of the~~ preparing a compound of formula I according to claim 1 ~~and~~ or a pharmaceutically ~~usable derivatives, solvates and stereoisomers thereof, characterised in that~~ acceptable salt, hydrate, alcoholate or stereoisomer thereof, comprising

a) reacting a compound of ~~the~~ formula II



II

in which

W, Y and T have the meanings indicated ~~in Claim 1~~ for the compound of formula I,

~~is reacted~~ with a compound of ~~the~~ formula III



III

in which

L denotes Cl, Br, I or a free or reactively functionally modified OH group, and

R^1, m, X and D have the meanings indicated ~~in Claim 1~~ for the compound of formula I,

or

b) for the preparation of ~~compounds of the~~ a compound of formula I, in which X denotes -C=O,

reacting a compound of ~~the~~ formula IV



IV

in which R^1, m, W, Y and T have the meanings indicated ~~in Claim 1~~ for the compound of formula I,

~~is reacted~~ with a compound of ~~the~~ formula V

D-CO-L V

in which

L denotes Cl, Br, I or a free or reactively functionally modified OH group, and

D has the meaning indicated ~~in Claim 1~~ for the compound of formula I,

or

c) for the preparation of ~~compounds of the~~ a compound of formula I in which X denotes CH_2,

reacting a compound of ~~the~~ formula IV



IV

in which R^1, m, W, Y and T have the meanings indicated ~~in Claim 1~~ for the compound of formula I,

~~is reacted~~ with a compound of ~~the~~ formula VI

D-CHO VI

in which

D has the meaning indicated ~~in Claim 1~~ for the compound of formula I,

in a reductive amination,

and/or

a base or acid of the compound of formula I is converted into one of its salts, hydrates or alcoholates.

19. (Currently Amended) ~~Compounds of the formula I according to claim 1 as inhibitors of~~ A method for inhibiting coagulation factor Xa, comprising administering a compound of formula I according to claim 1 in an effective amount to inhibit coagulation factor Xa.

20. (Currently Amended) ~~Compounds~~ A compound of ~~the~~ formula I according to claim 1 as inhibitors of coagulation factor VIIa, comprising administering a compound of formula I according to claim 1 in an effective amount to inhibit coagulation factor VIIa.

21. (Currently Amended) ~~Medicaments comprising at least one~~ A pharmaceutical composition comprising a compound of ~~the~~ formula I according to claim 1 and/or a pharmaceutically ~~usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios, and optionally excipients and/or adjuvants~~ acceptable salt, hydrate, alcoholate or stereoisomer thereof, or a mixture thereof, and a pharmaceutically acceptable excipient and/or adjuvant.

22. (Currently Amended) ~~Medicaments comprising at least one compound of the formula I according to claim 1 and/or pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios, and at least one further medicament~~ A pharmaceutical composition according to claim 21, further comprising a pharmaceutically active ingredient other than the compound of formula I.

23. (Withdrawn and Currently Amended) ~~Use of compounds according to claim 1 and/or physiologically acceptable salts and solvates thereof for the preparation of a medicament for the treatment of~~ A method for treating thromboses, myocardial infarction, arteriosclerosis, inflammation, apoplexy, angina pectoris, restenosis after angioplasty, claudicatio intermittens, migraine, ~~tumours, tumour diseases and/or tumour metastases~~ a tumor, a tumor disease and/or tumor metastases, comprising administering to a subject in need thereof an effective amount of a pharmaceutical composition according to claim 21.

24. (Currently Amended) ~~Set (kit) consisting of~~ A set or kit comprising separate packs of

(a) ~~an effective amount of~~ a compound of ~~the~~ formula I according to claim 1 and/or a pharmaceutically ~~usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios~~ acceptable salt, hydrate, alcoholate or stereoisomer thereof, or a mixture thereof,

and

(b) ~~an effective amount of a further medicament~~ a pharmaceutically active ingredient other than the compound of formula I.

25. (New) A compound of formula I



I

in which

D denotes aromatic carbo- or heterocycle having 0 to 4 N, O and/or S atoms which is unsubstituted or mono- or polysubstituted by Hal, A, OR^2, $N(R^2)_2$, NO_2, CN, $COOR^2$ or $CON(R^2)_2$,

X denotes -C=O or $C(R^3)_2$,

W denotes $-[C(R^3)_2]_n-$,

R^1 denotes H or A, which may be substituted by OR^3, $S(O)_nR^3$, $N(R^3)_2$, CN, $COOR^3$, $CON(R^3)_2$, $OCON(R^3)_2$, $N(R^3)COOR^3$, $N(R^3)CON(R^3)_2$, $N(R^3)SO_2R^3$, $SO_2N(R^3)_2$ or -C≡C-,

R^2 denotes H, A, $-[C(R^3)_2]_n$-Ar', $-[C(R^3)_2]_n$-Het', $-[C(R^3)_2]_n$-cycloalkyl, $-[C(R^3)_2]_n$-$N(R^3)_2$ or $-[C(R^3)_2]_n$-OR^3,

R^3 denotes H or A,

Y denotes alkylene, cycloalkylene, Het-diyl or Ar-diyl,

T denotes a mono- or bicyclic saturated, unsaturated or aromatic carbo- or heterocycle having 0 to 4 N, O and/or S atoms which is mono- or disubstituted by =O, =S, $=NR^2$, =N-CN, $=N-NO_2$, $=NOR^2$, $=NCOR^2$, $=NCOOR^2$, and/or $=NOCOR^2$ and may furthermore be mono-, di- or trisubstituted by R^2, Hal, A, $-[C(R^3)_2]_n$-Ar, $-[C(R^3)_2]_n$-Het, $-[C(R^3)_2]_n$-cycloalkyl, OR^2, $N(R^2)_2$, NO_2, CN, $COOR^2$, $CON(R^2)_2$, NR^2COA, $NR^2CON(R^2)_2$,

NR^2SO_2A, COR^2, SO_2NR^2 and/or $S(O)_nA$,

A denotes unbranched or branched alkyl having 1-10 C atoms, in which one or two CH_2 groups may be replaced by O or S atoms and/or by -CH=CH- groups and/or 1-7 H atoms may be replaced by F,

Ar denotes phenyl, naphthyl or biphenyl, each of which is unsubstituted or mono-, di- or trisubstituted by Hal, A, OR^2, $N(R^2)_2$, NO_2, CN, $COOR^2$, $CON(R^2)_2$, NR^2COA, $NR^2CON(R^2)_2$, NR^2SO_2A, COR^2, $SO_2N(R^2)_2$, $S(O)_nA$, $-[C(R^3)_2]_n-COOR^2$ or $-O-[C(R^3)_2]_o-COOR^2$,

Ar' denotes phenyl which is unsubstituted or mono-, di- or trisubstituted by Hal, A, OR^3, $N(R^3)_2$, NO_2, CN, $COOR^3$, $CON(R^3)_2$, NR^3COA, $NR^3CON(R^3)_2$, NR^3SO_2A, COR^3, $SO_2N(R^3)_2$, $S(O)_nA$, $-[C(R^3)_2]_n-COOR^3$ or $-O-[C(R^3)_2]_o-COOR^3$,

Het denotes a mono- or bicyclic saturated, unsaturated or aromatic heterocycle having 1 to 4 N, O and/or S atoms, which may be unsubstituted or mono-, di- or trisubstituted by carbonyl oxygen, $=S$, $=N(R^2)_2$, Hal, A, $-[C(R^3)_2]_n-Ar$, $-[C(R^3)_2]_n-Het'$, $-[C(R^3)_2]_n-$cycloalkyl, $-[C(R^3)_2]_n-OR^2$, $-[C(R^3)_2]_n-N(R^3)_2$, NO_2, CN, $-[C(R^3)_2]_n-COOR^{2'}$, $-[C(R^3)_2]_n-CON(R^2)_2$, $-[C(R^3)_2]_n-NR^2COA$, $NR^2CON(R^2)_2$, $-[C(R^3)_2]_n-NR^2SO_2A$, COR^2, SO_2NR^2 and/or $S(O)_nA$,

Het' denotes a mono- or bicyclic saturated, unsaturated or aromatic heterocycle having 1 to 4 N, O and/or S atoms, which may be unsubstituted or mono- or disubstituted by carbonyl oxygen, $=S$, $=N(R^3)_2$, Hal, A, OR^3, $N(R^3)_2$, NO_2, CN, $COOR^3$, $CON(R^3)_2$, NR^3COA, $NR^3CON(R^3)_2$, NR^3SO_2A, COR^3, SO_2NR^3 and/or $S(O)_nA$,

Hal denotes F, Cl, Br or I,

m denotes 1 or 2,

n denotes 0, 1 or 2, and

o denotes 1, 2 or 3,

or a pharmaceutically acceptable salt thereof.